?

        當(dāng)前位置:對(duì)照品 > 實(shí)驗(yàn)試劑 > 生化試劑 >
        XL-147, ≥98%
        ??【編號(hào)】:127130

        ??【產(chǎn)品名稱】:XL-147, ≥98%

        ??【規(guī)格】:5MG

        ??【用途】:

          XL-147, ≥98%

          Product Name: XL-147
          CAS號(hào):934526-89-3
          分子式:C25H25ClN6O4S
          分子量:541.02
          貯存: 儲(chǔ)存溫度-20°C
          可溶性: 25°C: DMSO 3 mg/mL; Water <1 mg/mL; Ethanol <1 mg/mL
          生化和生理學(xué)機(jī)理:
          Description:
          IC50 Value:39 nM (PI3Kα); 383 nM (PI3Kβ); 36 nM (PI3Kδ); 23 nM(PI3Kγ) [1]
          XL147 is a potent, orally bioavailable inhibitor of the class I PI3K family of lipid kinases with IC50 values in the nanomolar range in biochemical assays.
          in vitro: XL147 binds in an ATP-competitive and reversible manner, yet is highly selective against a panel of >130 human protein kinases. In cellular assays, XL147 antagonizes the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) resulting in inhibition of phosphorylation of several downstream effectors of PI3K including Akt, ribosomal S6 kinase, and ribosomal S6 protein [1].Compared with XL147 alone, the combination exhibited a superior antitumor effect against trastuzumab-resistant tumor xenografts. Furthermore, treatment with XL147 and trastuzumab reduced the cancer stem-cell (CSC) fraction within trastuzumab-resistant cells both in vitro and in vivo [2].
          in vivo: SAR245408 induced significant differences in EFS distribution compared to control in 29 of 37 (79%) of solid tumor xenografts and in two of seven (29%) ALL. Xenografts. SAR245408 induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity (EFS T/C?>?2) in 4 of 37 (11%) solid tumor xenografts [3].
          Toxicity: In vitro SAR245408 demonstrated cytotoxic activity, with a median relative IC50 value of 10.9??M (range 2.7-24.5??M) [4].
          Clinical trial: Open-label Treatment Extension Study With SAR-245408 or SAR-245409 as a Monotherapy or as a Combination Regimen. Phase 1/Phase 2
        上一篇:XMD8-92, ≥99% 下一篇:YK-4-279



          ?
          首 頁 | 對(duì)照品| 標(biāo)準(zhǔn)品| 標(biāo)準(zhǔn)物質(zhì)| 實(shí)驗(yàn)試劑| 培養(yǎng)基| 菌種購買| 新聞中心| 聯(lián)系我們| 網(wǎng)站地圖

          2011-2018 北京萊耀生物版權(quán)所有豫ICP備17046142號(hào)

          ? 主站蜘蛛池模板: 翁源县| 洛阳市| 阿尔山市| 芜湖市| 巴青县| 宜兴市| 汝南县| 南昌县| 龙山县| 万宁市| 和平县| 宁乡县| 冷水江市| 延寿县| 曲麻莱县| 呼伦贝尔市| 钟祥市| 长子县| 青阳县| 古交市| 怀柔区| 西林县| 缙云县| 江孜县| 贵州省| 永丰县| 濮阳市| 永修县| 孝义市| 砚山县| 夏津县| 镇远县| 杨浦区| 奎屯市| 长海县| 奇台县| 同德县| 乌审旗| 稻城县| 铅山县| 潞城市|